NCT00220194已完成4 期
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
San Bernardino Urological Associates Medical Group Inc1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2003年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 1
研究概览
简要总结
Comparing the effect of switching from Lupron and Zoladex to Eligard. PSA and Testosterone levels are measured at set intervals to determine if Eligard is equal or better then Lupron or Zoladex in advanced Prostate Cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patient with Advanced Ca, on stable dose of Lupron or Zoladex
排除标准
- •Previous exposure to Eligard.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.HypogonadismObesityNCT03619330University Medical Centre Ljubljana30
已完成
2 期
Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or PlaceboSeizure DisorderHypogonadismErectile DysfunctionNCT00179517Beth Israel Deaconess Medical Center40
已完成
2 期
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for MetastasesProstatic NeoplasmsNCT04523207Janssen Research & Development, LLC108
终止
4 期
Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate CancerProstate CancerNCT02749825Pharmatech41
已完成
3 期
A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In PatientsOpen-angle GlaucomaOcular HypertensionGlaucomaNCT00856622Pfizer's Upjohn has merged with Mylan to form Viatris Inc.436